Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Short Interest Update

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) saw a large increase in short interest during the month of April. As of April 15th, there was short interest totalling 2,800,000 shares, an increase of 16.7% from the March 31st total of 2,400,000 shares. Based on an average daily volume of 1,520,000 shares, the short-interest ratio is presently 1.8 days. Currently, 2.5% of the company’s shares are short sold.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. StockNews.com lowered shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, March 4th. The Goldman Sachs Group increased their target price on shares of Amneal Pharmaceuticals from $5.50 to $6.25 and gave the company a “buy” rating in a report on Monday, March 4th. Piper Sandler raised their price target on shares of Amneal Pharmaceuticals from $6.00 to $8.00 and gave the stock an “overweight” rating in a report on Thursday, March 21st. Finally, Barclays raised their price target on shares of Amneal Pharmaceuticals from $6.00 to $8.00 and gave the stock an “overweight” rating in a report on Monday, January 29th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $7.31.

Institutional Investors Weigh In On Amneal Pharmaceuticals

A number of large investors have recently modified their holdings of the stock. Assenagon Asset Management S.A. boosted its stake in shares of Amneal Pharmaceuticals by 271.7% during the 1st quarter. Assenagon Asset Management S.A. now owns 546,537 shares of the company’s stock valued at $3,312,000 after purchasing an additional 399,492 shares in the last quarter. Sanders Morris Harris LLC purchased a new position in Amneal Pharmaceuticals during the 1st quarter valued at about $1,513,000. Bellevue Group AG purchased a new position in Amneal Pharmaceuticals during the 4th quarter valued at about $155,000. CastleKnight Management LP purchased a new position in Amneal Pharmaceuticals during the 4th quarter valued at about $604,000. Finally, Rubric Capital Management LP lifted its position in Amneal Pharmaceuticals by 98.8% during the 4th quarter. Rubric Capital Management LP now owns 8,000,000 shares of the company’s stock valued at $48,560,000 after acquiring an additional 3,975,500 shares during the period. Institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Trading Down 0.5 %

Shares of AMRX opened at $5.87 on Monday. The firm’s 50-day moving average price is $5.72 and its 200-day moving average price is $5.21. The firm has a market capitalization of $1.80 billion, a price-to-earnings ratio of -18.93 and a beta of 1.33. The company has a current ratio of 1.63, a quick ratio of 0.94 and a debt-to-equity ratio of 121.31. Amneal Pharmaceuticals has a 1-year low of $1.72 and a 1-year high of $6.46.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its earnings results on Friday, March 1st. The company reported $0.12 earnings per share for the quarter, beating analysts’ consensus estimates of $0.05 by $0.07. The firm had revenue of $616.98 million for the quarter, compared to analyst estimates of $630.67 million. Amneal Pharmaceuticals had a negative net margin of 3.51% and a positive return on equity of 126.04%. Sell-side analysts anticipate that Amneal Pharmaceuticals will post 0.5 EPS for the current year.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.